100 results about "Placental tissue" patented technology

Cells derived from postpartum placenta and methods for their isolation are provided by the invention. The invention further provides cultures and compositions of the placenta-derived cells. The placenta-derived cells of the invention have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications.

Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.

A stent scaffold combined with amniotic tissue provides for a biocompatible stent that has improved biocompatibility and hemocompatibility. The amnion tissue can be variously modified or unmodified form of amnion tissue such as non-cryo amnion tissue, solubilized amnion tissue, amnion tissue fabric, chemically modified amnion tissue, amnion tissue treated with radiation, amnion tissue treated with heat, or a combination thereof. Materials such as polymer, placental tissue, pericardium tissue, small intestine submucosa can be used in combination with the amnion tissue. The amnion tissue can be attached to the inside, the outside, both inside and outside, or complete encapsulation of the stent scaffold. In some embodiments, at least part of the covering or lining comprises a plurality of layers of amnion tissue. The method of making the biocompatible stent and its delivery and deployment are also discussed.

The invention relates to a method for freezing and thawing placental whole cells and separating and expanding stem cells. The method comprises the steps as follows: disinfecting and washing a placenta tissue; cutting off placental lobules from the tissue, and carrying out digestive treatment for 20 min; preparing a placenta tissue freezing solution for standby application; adding whole cells obtained by digestive treatment and the freezing solution into a freezing tube, refrigerating for 0.5 h at the temperature of 4 DEG C, freezing for 1 day at the temperature of subzero 80 DEG C, and freezing in liquid nitrogen for standby application; taking out the placental whole cells from the liquid nitrogen when needed, thawing in a thermostatic water bath, carrying out drop-method washing by a culture medium for mesenchymal stem cells, removing red cells by a red cell lysis solution, and expanding the mesenchymal stem cells by the thawed placental whole cells through cell culture and cell passage. According to the method, the frozen placenta tissue can be effectively protected and is convenient to thaw and use; and the method is in particular suitable for separating and expanding the mesenchymal stem cells after thawing the frozen placental tissue.

Provided herein are biocompatible polymer conjugates comprising a biologically compatible polymer covalently bound to a biologically compatible chelator moiety, which in turn are optionally bound, reversibly, to pharmacologically active metal ions. The biologically compatible polymer may comprise of modified placental tissue grafts composed of at least one membrane, capable of recruiting stem cells in vivo and in vitro.

The invention discloses a placenta stem cell bank construction method and a placenta tissue resuscitation method, and relates to placenta stem cell bank construction methods. The placenta stem cell bank construction method comprises the following steps: after non-bacterial cleaning treatment to placenta tissues of at least three parts, the steps of tissue peeling, further sterilizing, shearing to be thin, protecting using a refrigerant, programmed freezing, cryogenic temperature temporary storage, long term storage with nitrogen canisters, and the like are carried out, and the placenta tissue with biological activities can be preserved for a long term. The placenta tissue preserved through the method can be used for the construction of a stem cell bank, resuscitation, enzymic digestion, cultivation, expansion, quality inspection and the like are performed after selective tissue part resuscitation according to required cell types, so as to obtain placenta amniotic membrance epithelial cells, placenta amniotic membrance mesenchyme, placenta chorion mesenchymal stem cell, placenta decidua serotina mesenchymal stem cells and the like. The method provided by the invention has the advantages that operation steps are simplified, manual intervention errors are reduced, the efficiency is improved, more stem cell resources are preserved, and a basis is provided for further personalized stem cell customization.

A placental tissue assembly for treating wounds or surfaces of a patient has one or more layers of placental tissue and a backing material. The one or more layers of placental tissue have a first side and a second side. The backing material is adhered to and covers one of either the first or second sides of the one or more layers of placental tissue to create the assembly. The assembly when applied onto a surface to be treated on the side of the tissue opposite the backing material adheres to the surface with an attachment force greater than an attachment force of the backing material adhered to the first or second side. This allows the backing material to be released leaving the placental tissue affixed to the surface to be treated.

The invention discloses four cell types which have wide heteroplastic transplantation application prospect and can be effectively induced into induced pluripotent stem (iPS) cells. The origins of three cell types are placental tissue, namely amnion mesenchymal cell, chorion mesenchymal cell and umbilical cord mesenchymal cell; and the origin of the other one is amniotic fluid cell. Besides, the invention also discloses an induction reprogramming method for producing cells capable of producing induced pluripotent stem (iPS) cells by efficient induction, including the following steps: cDNA containing pluripotent stem cell factor is respectively introduced into the four primary culture cells; the four primary cells in which cDNA is introduced are respectively cultured on appropriate culture mediums, primary iPS is obtained and then quality of iPS is optimized on appropriate culture mediums, and cloning of pluripotent stem cell can be primarily evaluated. In the invention, three mesenchymal cells of placenta origin and amniotic fluid cell all can be induced into iPS, wherein the chorion mesenchymal cell is compared with fibroblast, efficiency of induction reprogramming is improved by over 100 times, efficiency is about 2.3%, and the efficiency is slightly higher than that of horny cell; and a means which is more effective and more pertinent is provided for building disease model, screening drug and controlling oriented differentiation.

The present invention includes a growth factor profile, connective tissue matrix constituents, and immunoprivileged status of equine placental tissue extracellular matrix (ECM) and accompanying cutaneous tissue, plus the presence of antimicrobial peptides there, render equine placental tissue an ideal source for biological scaffolds for xenotransplantation, and optionally adding at least one of: one or more block-copolymers, one or more osteogenic agent or one or more osteoinductive agents.

Enhanced postnatal adherent cells and a preparation method therefor are provided. The preparation method of enhanced postnatal adherent cells can increase the yield and the proliferation rate of adherent cells from placental tissues; and prepare adherent cells, which secrete proteins effective for neurological diseases and have an improved ability for movement to damaged tissues.

The invention provides a stem cell growth factor based striae gravidarum repair product. The product comprises, by volume fraction, 45% of umbilical cord mesenchymal stem cell cytokine supernatant, 50% of placenta tissue extract liquid, 5% of human serum albumin, vitamin E in final concentration of 20IU/ml, vitamin C in final concentration of 50microgram/ml and vitamin B5 in final concentration of100microgram/ml. The striae gravidarum repair product has the advantage that by combination of various cell growth factors secreted in a human mesenchymal stem cell culture process and active components extracted from human placental tissues, striae gravidarum can be repaired effectively.

Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion which has been decellularized and at least one layer of chorion. Also described herein are methods for making and using the tissue grafts.

The invention discloses a separation method of human placenta mesenchymal stem cells. The separation method comprises the following steps that placenta specimen treatment is carried out, treated placenta tissue is obtained, tissue digestion is carried out on the placenta tissue, and cell suspension is obtained; preliminary subculture of the placenta mesenchymal stem cells is carried out; further separation and culture of the placenta mesenchymal stem cells are carried out. HyQTase and DNAse I are adopted for digestion together, the placenta mesenchymal stem cells are obtained through separation, after preliminary culture, microgravity treatment and electromagnetic field and sound wave treatment are carried out, BMP4 is used for treatment many times, upper layers are removed through a differential attachment method, a serum-free medium and antioxidant are replenished in a culture bottle for culture, and the final purity is high. The stem cell characteristics of the cells are verified through detection on hereditary stability, cell surface molecule expression conditions and cellular morphology in the continuous passage process, and materials are provided for seed cells with the placenta mesenchymal stem cells as clinical application.

The invention discloses a method for preparing a medical multilayer placental tissue implant. The method for preparing the medical multilayer placental tissue implant comprises the following steps of obtaining a qualified placental tissue material, separating amnion and chorionic tissue from the placental tissue material, treating the amnion and the chorionic tissue, removing blood, cells and DNA, disinfecting decellularized tissue, conducting lamination drying, cutting, and completing preparation. The medical multilayer placental tissue implant has a better adhesion effect on deep wounds, and is strong in toughness and not easy to tear.

The invention discloses a sheep stem extract and its preparation method and application, and discloses a preparation method of its preparation freeze-dried powder. The sheep stem extract is obtained by separating and culturing amniotic mesenchymal stem cells from human placenta amniotic tissue, and using human platelets The lysate is cultured and expanded, and then the culture supernatant of human amniotic mesenchymal stem cells is collected, concentrated and collected, which solves the problems of long doubling time and poor multi-differentiation potential of AMSCs, and can qualitatively and Quantitative analysis can improve the active ingredients in sheep stems, such as antioxidants and various growth factors, and prevent the active ingredients from degrading. The results of animal experiments and clinical trials show that the sheep dry extract prepared by this technology can be used to delay aging, prevent and treat osteoporosis and skin aging, and promote skin wound healing.